



The Role of Diacylglycerol Kinase in the Amelioration of Diabetic Nephropathy

Hayashi, Daiki
Shirai, Yasuhito

(Citation)

Molecules, 27(20):6784

(Issue Date)

2022-10

(Resource Type)

journal article

(Version)

Version of Record

(Rights)

© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

(URL)

<https://hdl.handle.net/20.500.14094/0100477411>



Review

The Role of Diacylglycerol Kinase in the Amelioration of Diabetic Nephropathy

Daiki Hayashi *  and Yasuhito Shirai * 

Department of Applied Chemistry in Bioscience, Graduate School of Agricultural Science, Faculty of Agriculture, Kobe University, Kobe 657-8501, Japan

* Correspondence: dhayashi@port.kobe-u.ac.jp (D.H.); shirai@kobe-u.ac.jp (Y.S.);

Tel.: +81-78-803-5855 (D.H.); +81-78-803-5887 (Y.S.)

Abstract: The drastic increase in the number of patients with diabetes and its complications is a global issue. Diabetic nephropathy, the leading cause of chronic kidney disease, significantly affects patients' quality of life and medical expenses. Furthermore, there are limited drugs for treating diabetic nephropathy patients. Impaired lipid signaling, especially abnormal protein kinase C (PKC) activation by de novo-synthesized diacylglycerol (DG) under high blood glucose, is one of the causes of diabetic nephropathy. DG kinase (DGK) is an enzyme that phosphorylates DG and generates phosphatidic acid, i.e., DGK can inhibit PKC activation under diabetic conditions. Indeed, it has been proven that DGK activation ameliorates diabetic nephropathy. In this review, we summarize the involvement of PKC and DGK in diabetic nephropathy as therapeutic targets, and its mechanisms, by referring to our recent study.

Keywords: diabetic nephropathy; protein kinase C; diacylglycerol kinase; 67 kDa laminin receptor



Citation: Hayashi, D.; Shirai, Y. The Role of Diacylglycerol Kinase in the Amelioration of Diabetic Nephropathy. *Molecules* **2022**, *27*, 6784. <https://doi.org/10.3390/molecules27206784>

Academic Editor: Igor Ivanov

Received: 12 September 2022

Accepted: 7 October 2022

Published: 11 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Diabetes and Diabetic Nephropathy

Diabetes is a chronic metabolic disease that causes high blood glucose levels, resulting in serious health problems and death. In 2021, the number of people living with diabetes globally was estimated to be 536.6 million (prevalence: 10.5%), and this number is expected to reach 783.2 million (prevalence: 12.2%) by 2045 [1]. Diabetes significantly increases the risk of various health issues such as heart attacks, strokes, and infections compared to healthy individuals [2,3]. Diabetes also causes serious vascular complications. Diabetic retinopathy, neuropathy, and nephropathy are major microvascular complications of diabetes caused by microangiopathy. These complications lead to blindness, gangrene, and end-stage renal disease, respectively. Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) in the world, leading to the need for dialysis, reducing patients' quality of life, and increasing medical care expenses.

DN causes glomerular filtration failure that leads to uremia in one in three diabetic patients after several years of latency [4]. Since a high blood glucose level is the fundamental cause of the complications, delaying the onset of DN by controlling the blood glucose level is the primary treatment strategy [5]. Recently, many drugs to control blood glucose levels, such as insulin, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists, have become available. It is also well recognized that the renin-angiotensin-aldosterone system (RAAS), which controls arterial pressure, plays a pivotal role in the pathogenesis of DN. So far, drugs targeting the RAAS, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), have been the first choice for preventing and delaying the onset of DN. However, there are limits to the drugs available for DN, and there are no specific therapeutics for ameliorating DN once hyperglycemia and high blood pressure become uncontrolled. Although controlling blood glucose levels is the most simple and effective approach to delaying the onset of microvascular complications, and inhibiting RAAS is effective for

DN, finding a novel target with a renoprotective effect was necessary. Therefore, to develop a novel drug for DN, it was vital to understand the mechanisms of the development and progression of DN and find an effective therapeutic target.

2. Hyperglycemia Impairs Lipid Signaling

Among the causes of DN, impaired lipid signaling, especially diacylglycerol (DG) signaling, is well known. Generally, DG is produced from phosphatidylinositol 4,5-bisphosphate [PI(4,5)P₂] and phosphatidylcholine (PC) by the action of phosphoinositide-specific phospholipase C (PI-PLC) and PC-specific PLC (PC-PLC) upon various growth factors and T-cell receptors (TCR) (Figure 1) [6–8]. In addition, DG is generated from the dephosphorylation of phosphatidic acid (PA) by phosphatidate phosphohydrolases (PAPs), including lipins [9,10]. PA is generated by hydrolyzing PC by phospholipase D (PLD) [11] and de novo synthesis from glycerol [12]. Glyceraldehyde 3-phosphate, an intermediate of glycolysis, is reversibly isomerized into dihydroxyacetone-phosphate and produces glycerol 3-phosphate. The glycerol 3-phosphate undergoes acylation and generates phosphatidic acid (PA), and dephosphorylates PA into DG (Figure 1). Under hyperglycemic conditions, excess blood glucose is uptaken intracellularly by the glucose transporter (GLUT) [13,14], and excess intracellular glucose results in DG production by de novo synthesis [12]. Both DG and PA are important intermediates for membrane lipids and are bioactive lipids involved in various signal transductions. For example, DG regulates conventional and novel protein kinase C (cPKC and nPKC) [15,16], Ras guanyl nucleotide-releasing protein (RasGRP) [17], and transient receptor potential channel (TRPC) [18]. PA regulates atypical PKC (aPKC) [19], phosphatidylinositol-4-phosphate 5-kinase (PI4P5K) [20], Raf-1 kinase [21], and mammalian target of rapamycin (mTOR) [22]. Therefore, abnormal DG production causes severe changes in their signaling pathways. The abnormal activation of cPKC and nPKC has been reported as a cause of DN.




Figure 1. Generation pathways of DG and pathways leading to diabetic nephropathy. P: phosphate.

3. Diabetic Nephropathy and PKC

PKC is a family of serine/threonine kinases, and nine mammalian isozymes are categorized into three groups based on their domain structure and characteristics [23]. cPKC (PKC α , β , γ) possesses diacylglycerol (DG) binding C1 domains (C1A and C1B) and a Ca²⁺ binding C2 domain, and their activity depends on DG and Ca²⁺ [24,25]. nPKC (PKC δ , ϵ , η , θ) has a slightly different domain composition than cPKC and lost Ca²⁺ dependency [26]. The DG-responsive characteristics of cPKC and nPKC are crucial to the pathogenesis of DN. The final subfamily requires neither Ca²⁺ nor DG for its activity and was cloned and classified as aPKC (PKC ι , ζ). It is activated by PA [27,28]. These PKCs phosphorylate many proteins, including receptors, transporters, kinases, and phosphatases; thus, PKCs play a central role in cell signaling [23]. To date, the increase in DG mass and

the abnormal activation of cPKC and nPKC under hyperglycemic conditions have been observed in vivo and in vitro [29–31], and evidence supports the idea that the abnormal activation of cPKC and nPKC is one of the causes of the development and progression of diabetic nephropathy [32–35].

Abnormally activated PKC causes various biological changes, such as growth factor upregulation, extracellular matrix production, and oxidative stress increase (Figure 1). Among PKC isozymes, activation of PKC α , β (cPKC) and PKC ϵ , δ (nPKC) have been observed in DN [28,34–38]. One of the mechanisms underlying how PKC activation causes DN is related to various growth factors [39]. The upregulation of transforming growth factor- β (TGF- β) signaling, a profibrotic cytokine, is considered a critical pathogenic and progression factor of DN by activating various signal transductions, expression of the extracellular matrix, and reactive oxygen species production [40,41]. It has been reported that diabetes-induced activation of PKC β and PKC δ upregulates TGF- β expression and the sensitivity of the cell against TGF- β , promoting the production of the extracellular matrix [42,43]. In addition to TGF- β , connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) are also recognized as key factors in DN progression [37]. CTGF is known to promote extracellular matrix production, leading to fibrosis [44]. VEGF is known as an angiogenic factor promoting vascular endothelial cell proliferation and pathological angiogenesis [45]. Several studies have reported that activation of PKC α , β , and ϵ upregulates VEGF expression [46,47], and PKC β upregulates CTGF expression [34]. Therefore, PKC inhibition can normalize these growth factor expressions and signaling and ameliorate DN. Moreover, PKC α and β are associated with reactive oxygen species (ROS) production by activation of NADPH oxidase, causing renal injury [34,48].

To develop drugs targeting abnormal PKC activation, a PKC β -specific inhibitor, ruboxistaurin, was developed and showed a renoprotective effect in several animal studies [49,50]. However, in human clinical trials, although ruboxistaurin showed some renoprotective effect in diabetes patients, statistical significance was not observed compared to placebo patients [35]. Furthermore, since DG–PKC pathway activation is a common event in other diabetic microvascular complications, ruboxistaurin underwent phase 3 clinical trials for diabetic retinopathy. Nevertheless, the trial failed due to the insignificance of its effect on retinopathy compared to the placebo group [51]. Taken together, the upregulation of the DG–PKC pathway in diabetes is one of the key events in the pathogenesis and progression of DN. However, since several independent PKC isoforms are involved in complex and multifactorial pathways, developing a drug targeting PKC is not simple. For example, PKC α deficiency prevents albuminuria by reducing VEGF. However, glomerular hypertrophy is not inhibited due to no change in TGF- β expression [33]. In contrast, PKC β deficiency prevents glomerular hypertrophy by reducing TGF- β but not albuminuria in mice [34,52]. Therefore, inhibiting a single PKC might be insufficient to prevent DN. One can overcome this by developing a pan-inhibitor for cPKC and nPKC, or a combination of several specific inhibitors, though issues with side effects may emerge.

4. Diabetic Nephropathy and DGK

DG kinase (DGK) is a family of enzymes that converts DG into PA by phosphorylation [53]. As illustrated in Figure 1, DGK is a central regulator in various signaling pathways related to DG and PA [54]. Since DGKs consume DG, DGK is recognized as an indirect inhibitor of cPKC and nPKC. So far, 10 subtypes of mammalian DGKs have been discovered and divided into Type I–V based on their structural characteristics [54–57]. All mammalian DGKs have several C1 domains homologous to the one of PKCs at the nitrogen ends of catalytic domains (CD). Type I DGKs (DGK α , β , γ) have a recoverin homology (RVH) domain and two EF-hand motifs, which bind to Ca²⁺ at the nitrogen end of the two C1 domains [58]. Type II DGKs (DGK δ , η , κ) are characterized by a split CD, with a pleckstrin homology domain (PH domain) at the N terminus. Among Type II DGKs, DGK δ and η have a sterile α motif domain (SAM domain) at the C terminus [59–61]. DGK ϵ has a simple structural feature composed of two C1 domains and a CD and is the only Type

III DGK subtype [62]. Type IV DGKs (DGK ζ , ι) possess ankyrin repeats at the C terminus, and residue between the C1 domains and the CD have homologs to the myristoylated alanine-rich C-kinase substrate phosphorylation site [63–65]. Type V DGKs (DGK θ) is the only subtype that has three C1 domains, and a PH domain overlapping the Ras-associating domain (RA domain) is localized between the C1 domains and the CD [66]. In addition, splicing variants to alter their domain composition has been reported in several subtypes.

Vitamin E is a hydrophobic antioxidant agent, and α -tocopherol is the most active vitamin E compound that humans preferentially absorb [67]. The main function of α -tocopherol is its antioxidant effect, preventing lipid peroxidation in the cell membrane [68]. In 1997, it was reported that α -tocopherol ameliorates the symptoms of DN by activating DGK and inhibiting glomerulus PKC in diabetic rats, suggesting the possibility of DGK as a therapeutic target for DN [69,70]. However, the subtype of DGK involved in the amelioration was unclear. In 2005, it was revealed that a Type I DGK, DGK α , is sensitive to α -tocopherol among the DGKs expressed in the murine glomeruli (DGK α , γ , δ , ϵ , and ζ) [71], i.e., in the cultured cell, α -tocopherol induced translocation of GFP tagged DGK α to the plasma membrane, which is the hallmark of DGK activation, while the other DGKs did not [72,73]. Although the primary function of α -tocopherol as a vitamin is its antioxidant effect, several studies have reported that the antioxidant effect of α -tocopherol is not related to PKC inhibition [74,75]. Indeed, it was revealed that the antioxidant effect of α -tocopherol is not necessary to activate DGK α [73]. There is a report showing that the antioxidant effect of α -tocopherol plays a protective role against the loss of activity of DGK α under the high glucose condition [76]. The detailed mechanisms of DGK α activation by α -tocopherol are discussed in a later section.

After discovering that α -tocopherol activates DGK α using DGK α deficient mice, it was proven that DGK α was involved in the renoprotective effect of α -tocopherol [77]. Interestingly, the study did not observe any renoprotective effect of α -tocopherol, including inhibition of albuminuria, in the DGK α deficient mice, indicating DGK α is responsible for the renoprotective effect of α -tocopherol. This suggests that the antioxidant effect of α -tocopherol itself was insufficient for the amelioration of DN, although reduction of oxidative stress is a key factor for the amelioration of DN [77,78]. Furthermore, in addition to DGK α , DGK δ has been implicated in the amelioration of DN by α -tocopherol [71]. The study showed that α -tocopherol increased the activity of both Ca²⁺ dependent (DGK α) and independent subtypes (DGK δ). However, whether DGK δ is involved in the amelioration of DN in vivo is still unknown. Further, DGK α and DGK δ are involved in insulin secretion and tolerance, respectively [79,80]. Therefore, activating DGK α and DGK δ might be beneficial to diabetes itself, in addition to DN.

Based on the many positive observations of the effect of α -tocopherol on DN in animal studies, a human trial was conducted. In the trial, patients with diabetes were supplemented daily with 400 IU of vitamin E, and outcomes of cardiovascular and DN were followed for 4.5 years. However, the supplementation of vitamin E did not have a positive effect on the outcomes, indicating that the renoprotective effect of α -tocopherol is not expressed in humans [81]. Since vitamin E is an essential micronutrient for humans and deficiency of vitamin E is rare in general, perhaps the additional effect of vitamin E was masked. Still, some studies have reported the renoprotective effect of α -tocopherol in humans, so the effect of tocopherols on DN needs more careful investigation [82,83]. In any case, it was still important to find other agents responsible for activating DGK α .

In addition to the effect of α -tocopherol, the involvement of DGK α in the renoprotective effect of green tea polyphenols has been unveiled. In the early 2000s, several studies reported the positive effect of green tea polyphenols on DN. Yokozawa et al. reported that supplementation of green tea polyphenols ameliorated albuminuria in diabetic rats [84]. Further, Yamabe et al. reported the positive effect of epigallocatechin gallate (EGCG), the most active green tea polyphenol, on the symptoms of diabetic nephropathy in rats, along with downregulation of TGF- β expression [85]. However, the underlying mechanisms of the renoprotective effect of the polyphenols have been elusive [86]. Recently, we discovered

that EGCG activates DGK α , suggesting DGK α is involved in the renoprotective effect of green tea polyphenols [87]. Furthermore, using DGK α deficient mice, the effect of EGCG on DN was evaluated, and it was proven that DGK α is essential for the effect of EGCG on DN [88]. In the study, the amelioration effect of DN was assessed by oral administration of EGCG in DGK α deficient mice. These studies supported the idea that activation of DGK α is an attractive therapeutic target for DN.

Further, it was also found that the 3''-O-methylated EGCG (EGCG3''Me), which possesses high absorption in plasma, more effectively ameliorated DN than EGCG [88]. This indicated that green tea polyphenols, especially EGCG, could be a functional food for DN. Importantly, the significant DN ameliorating effect of EGCG was observed in a human trial [89]. It has been reported that EGCG can attenuate insulin resistance by inducing the translocation of GLUT4 [90,91]. Therefore, supplementation of EGCG may be recommended to prevent and ameliorate diabetes and DN. While there are two major issues that should be overcome for the use of EGCG for treating DN, daily consumption of green tea polyphenols can still be considered beneficial. One is toxicity, and the other is pharmacokinetics. High doses of EGCG are toxic [92], and the absorption of EGCG in plasma is low [93]. Although EGCG3''Me has improved pharmacokinetics, EGCG3''Me is a minor component of green tea polyphenols, and purification of EGCG3''Me is challenging. Therefore, finding an agent to overcome these issues is still required.

5. The Mechanisms of the Amelioration of DN by DGK α Activation

One of the mechanisms by which DGK α activation ameliorates DN is through PKC inhibition. While an inhibitor acts on a specific PKC subtype, DGK α activation can inhibit several PKCs simultaneously by reducing the amount of DG. This might be the benefit of targeting DGK α as a therapeutic target since several PKC species contribute to DN pathogenesis and progression. Indeed, it has been proven that α -tocopherol treatment inhibits the activation of both PKC β and PKC α in diabetic mice kidneys [94]. It has not been determined whether DGK α can inhibit PKC ϵ and PKC δ , but it is likely to inhibit both. Further, EGCG, a DGK α activating agent, ameliorates albuminuria with downregulation of TGF- β under diabetic conditions, indicating DGK α activation inhibits the downstream of PKCs, although direct evidence has not been obtained yet [95]. Based on this, DGK α activation can ameliorate DN by inhibiting various biological activities, followed by PKC activation.

Another important mechanism by which DGK α activation ameliorates DN is the protection of glomerular epithelial cells, and part of the effect might be independent of PKC inhibition. Glomeruli are composed of three types of cells: mesangial cells, vascular endothelial cells, and vascular epithelial cells (podocytes). It was found that DGK α is expressed abundantly in podocytes, suggesting DGK α contributes to the biological activity of podocytes [87]. The podocyte is a terminally differentiated cell that plays a critical role in filtration by forming a slit membrane structure that functions as a filtration barrier [96,97]. The slit membrane is a filter-like slit formed by interdigitated cell swellings called foot processes (FPs), lining the glomerular basement membrane (GBM) (Figure 2A,B). In many kidney diseases, including DN, barrier function is affected by FP flattening (called effacement) (Figure 2C) and loss of podocytes [98]. Our previous study revealed that DGK α activation protected against effacement and podocyte loss [77,88]. The inhibition of PKC α could be one of the mechanisms of its effect since it has been reported that PKC α promotes the endocytosis of nephrin, which localizes at tight junctions and plays a critical role in the barrier function of the slit membrane [99]. In addition to the tight junction, adhesion to GBM is also essential to maintaining the morphology of the slit membrane. α 3 β 1 integrin is involved in adhesion, and it has been reported that DGK α can recruit β 1 integrin to the peripheral membrane by generating PA [100–103]. Therefore, the recruitment of β 1 integrin is suggested to be one of the mechanisms of the effect. Indeed, EGCG treatment prevents loss of focal adhesion in the high glucose cultured human podocyte [88]. Further, a human trial observed protection against podocyte apoptosis by green tea polyphenols in DN [89]. In cancer cells, it is well known that DGK α prevents apoptosis via various

signaling pathways, followed by PA production [104–106], suggesting the involvement of DGK α in the prevention of apoptosis of podocytes by green tea polyphenols, especially EGCG. Taken together, DGK α activation ameliorates DN by not only inhibiting PKCs by reducing the amount of DG but also by generating PA activating downstream signaling pathways. In podocytes, DGK α activation plays a protective role in preventing loss and morphological changes to prevent DN.




Figure 2. Transmitted microscopy images of the slit membrane structure. (A) A transmitted electron microscopy image of the mouse glomerulus. (B) A zoomed-in image of the slit membrane structure. (C) A collapsed slit membrane structure in streptozocin (STZ)-induced diabetic mice glomerulus.

6. The Mechanisms of DGK α Activation

Given that DGK α is a potential therapeutic target for DN, the activator of DGK α could be a good candidate for drugs for DN. As described before, DGK α possesses an RVH domain, two EF-hand motifs, and two C1 domains (Figure 3A). These domains have been suggested to regulate intracellular localization and activation of DGK α . Indeed, intramolecular interactions between EF-hand motifs and C1 domains are important to restrict the activation of DGK α . In the inactive state, EF-hand motifs intramolecularly interact with C1 domains, and Ca²⁺ activates DGK α by releasing EF-hand motifs from C1 domains [54,107,108]. Several lipids, such as phosphatidyl serine (PS) [108,109], phosphatidyl inositol phosphates (PIPs) [110], and sphingosines [111,112], are also known to enhance DGK α activity. Interestingly, the lipid-binding C1 domains are not responsible for PS-induced activation, and PS activates DGK α by interacting with its CD [109]. Activation mechanisms of PIPs and sphingosines have not been revealed yet. Still, these endogenous activators directly activate DGK α since they all show the activation effect in in vitro assays using purified DGK α . Developing a drug for DN based on a direct activator of DGK α is a simple and reasonable idea. So far, in vitro screening has been conducted to discover DGK α activators/inhibitors and has identified two activators [113,114]. However, there was still difficulty finding and evaluating direct activators via only in vitro screening since an active enzyme is used for the assay. The three-dimensional structure of DGK α can help to design the activator. However, the three-dimensional structure was not available, other than the nuclear magnetic resonance (NMR) structure of the RVH domain (PDB ID: 1TUZ). Recently, the crystal structure of the EF-hand motifs was solved by X-ray, with good resolution (PDB ID: 6IIE) [115]. As shown in Figure 3B, the crystal structure revealed that two Ca²⁺ ions bind to distinct binding sites, mainly composed of acidic amino acids. Since the Ca²⁺ binding of EF-hand motifs is critical for the activation of DGK α , it is now possible to design DGK α activators targeting EF-hand motifs based on the crystal structure.

Furthermore, recent rapid evolution in the prediction of the protein structure by deep learning provides the predicted structure of DGK α by AlphaFold2, as shown in Figure 3C [116–118]. Notably, although the prediction scores of linker regions between each domain are not so high as predicting the orientation of these domains, the structure of each domain seemed to be reliable enough. Indeed, the predicted RVH domain and EF-hand motifs overlapped well with the experimental structures, and the root-mean-square deviations (RMSD) were 1.229 and 1.076 Å, respectively (Figure 3D,E). In other words,

taking advantage of the predicted structure makes it possible to understand the molecular basis of DGK α activation more deeply.




Figure 3. The structural features of DGK α . (A) Domain composition of human DGK α . (B) The residues contributing to the Ca²⁺ binding at EF-hand motifs of DGK α (PDB ID: 6IIE). (C) The predicted structure of human DGK α by AlphaFold2. The same color code as figure (A) was used. The comparisons of the predicted (D) RVH domain and (E) EF-hand motifs (cyan) with experimental structures (PDB ID: 1TUZ (purple) and 6IIE (green)). Gray particles are Ca²⁺.

In addition to the direct activation, it is well known that tyrosine-phosphorylation regulates the localization and activation of DGK α [73,119,120]. Phosphorylation at Tyr335 on the linker region between the C1 domains and CD induces activation and translocation of DGK α to the plasma membrane and is regulated by Src family tyrosine kinase [73,119]. Our previous study revealed that α -tocopherol indirectly activates DGK α through phosphorylation at Tyr335 by Src family tyrosine kinases [73]. However, the specific receptor contributing to the α -tocopherol-induced activation of DGK α has not been determined, although the contribution of some receptors has been suggested. This is because no membrane receptor for α -tocopherol has been discovered, although its existence has been suggested [121].

Independently, it was discovered that EGCG indirectly activates DGK α , and the 67 kDa laminin receptor (67LR) mediates the activation [88]. 67LR is primarily recognized as a receptor for laminin, and various ligands such as Sindbis virus and pathogenic prion protein have been reported [122–126]. In 2004, it was reported that EGCG is one of the ligands for 67LR [127]. So far, it has been recognized that 67LR mediates many functions of EGCG, such as the anti-cancer effect and toll-like receptor 4 (TLR4) signaling inhibition [128–130]. However, there remains controversy over how 67LR activates the downstream signaling pathway, although several candidates have been suggested [128,131]. Our previous study indicated that Src family tyrosine kinase mediates the EGCG-induced DGK α activation, as with α -tocopherol, and interacts with 67LR [88]. Notably, another group also reported the implementation of Src family tyrosine kinase in EGCG-67LR signaling [132].

Based on the similarity between EGCG and α -tocopherol-induced DGK α activation, we considered whether 67LR also mediates α -tocopherol-induced DGK α activation and revealed that 67LR functions as an α -tocopherol receptor mediating DGK α activation [133]. Interestingly, both EGCG and α -tocopherol directly bind to 67LR, but they bind to different residues; the former was hydrophilic, while the latter was hydrophobic (Figure 4A) [133]. Notably, the detailed binding mode of EGCG and α -tocopherol to their binding pocket were revealed in the study by taking advantage of hydrogen-deuterium exchange mass spectrometry (HDX-MS) and molecular dynamics (MD) simulation [133]. According to the binding mode, the binding of EGCG to the site was ruled by hydrogen bonds through many hydroxy groups of EGCG (Figure 4B). α -tocopherol exerts its antioxidant effect through the hydroxyl moiety, but the binding of α -tocopherol was ruled by hydrophobic interactions, and the hydroxyl group was not part of the binding (Figure 4B). This suggests that the antioxidant ability of α -tocopherol was not related to the binding to 67LR. These studies clarified that both EGCG and α -tocopherol activate DGK α through 67LR. In other words, 67LR agonists can activate DGK α . Therefore, 67LR agonists could be another target for treating DN as an indirect activator of DGK α , although further studies are needed. Further, the study indicated that 67LR is the first discovered cell surface receptor for vitamin E and suggested that 67LR mediates some functions of vitamin E. Although further investigation on the physiological role of binding between 67LR and vitamin E is required, the agonist of 67LR can compensate for some functions of vitamin E.




Figure 4. Hydrophobicity of the EGCG and α -tocopherol binding site of 67LR. (A) The amino acid residues of EGCG and the α -tocopherol binding site of 67LR are shown as surfaces colored by hydrophobicity (white: hydrophilic, red: hydrophobic. Green: EGCG, Blue: α -tocopherol). (B) The 2D binding mode of EGCG and α -tocopherol in each binding site. The 2D images are generated based on the binding mode of EGCG and α -tocopherol [133]. Green dashed lines indicate hydrogen bonds, and blue dashed lines indicate arene-hydrogen interactions with circled amino acids.

7. Conclusions

Under hyperglycemic conditions, high blood glucose results in DG accumulation via de novo synthesis. The accumulation of DG abnormally activates PKCs, and the enhanced PKC pathways are one of the mechanisms for the development and progression of DN. PKC activation promotes biological changes leading to DN, such as growth factor expression followed by extracellular matrix production and oxidative stress (Figure 5). DGK is an enzyme that can inhibit PKC activity by converting DG into PA. So far, many studies have supported the idea that DGK α ameliorates DN by inhibiting abnormal activation of PKCs and by activating PA signaling (Figure 5). Notably, since DGK α activation can inhibit several PKC subtypes simultaneously, DGK α activation may be more effective than specific PKC inhibitors. So far, it has been proven that two food factors, α -tocopherol, and EGCG, ameliorated DN through DGK α activation in murine studies. Importantly, EGCG showed a positive effect on DN in humans, suggesting that EGCG is a functional food for DN by activating DGK α , although there are several issues, such as toxicity of EGCG for medical purposes. Therefore, the development of an effective DGK α activator is still needed.




Figure 5. Schematic figure of the progression and pathogenesis of DN by the DG-PKC pathway and activation mechanism of DGK α .

Since DGK α inhibition can kill cancer cells and enhance T-cell function, the development of inhibitors has been focused on, and activators have received less attention [134–136]. Additionally, finding activators is generally challenging compared to finding inhibitors, which has delayed the development of activators. However, recently, state-of-the-art techniques have let us deeply understand the underlying mechanisms of DGK α activation and will enable the development of DGK α activators based on these mechanisms. Recently, it has been revealed that EGCG and α -tocopherol activate DGK α via 67LR binding, and their detailed binding mode has been elicited. Taken together, DGK α and its upstream 67LR are attractive therapeutic targets that normalize lipid signaling under diabetic conditions

for DN, and 67LR agonists could be designed based on the binding mode of EGCG and α -tocopherol.

Author Contributions: D.H. and Y.S. surveyed the literature and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. *Diabetes Res. Clin. Pract.* **2022**, *183*, 109119. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Sarwar, N.; Gao, P.; Kondapally Seshasai, S.R.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Stampfer, M.; et al. Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. *Lancet* **2010**, *375*, 2215–2222. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Carey, I.M.; Critchley, J.A.; Dewilde, S.; Harris, T.; Hosking, F.J.; Cook, D.G. Risk of Infection in Type 1 and Type 2 Diabetes Compared with the General Population: A Matched Cohort Study. *Diabetes Care* **2018**, *41*, 513–521. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Hovind, P.; Tarnow, L.; Rossing, P.; Jensen, B.R.; Graae, M.; Torp, I.; Binder, C.; Parving, H.H. Predictors for the Development of Microalbuminuria and Macroalbuminuria in Patients with Type 1 Diabetes: Inception Cohort Study. *Br. Med. J.* **2004**, *328*, 1105–1108. [\[CrossRef\]](#)
5. Samsu, N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. *Biomed. Res. Int.* **2021**, *2021*, 1497449. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Secrist, J.P.; Karnitz, L.; Abraham, R.T. T-Cell Antigen Receptor Ligation Induces Tyrosine Phosphorylation of Phospholipase C- Γ 1. *J. Biol. Chem.* **1991**, *266*, 12135–12139. [\[CrossRef\]](#)
7. Rhee, S.G.; Bae, Y.S. Regulation of Phosphoinositide-Specific Phospholipase C Isozymes. *J. Biol. Chem.* **1997**, *272*, 15045–15048. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Monick, M.M.; Carter, A.B.; Gudmundsson, G.; Mallampalli, R.; Powers, L.S.; Hunninghake, G.W. A Phosphatidylcholine-Specific Phospholipase C Regulates Activation of P42/44 Mitogen-Activated Protein Kinases in Lipopolysaccharide-Stimulated Human Alveolar Macrophages. *J. Immunol.* **1999**, *162*, 3005–3012.
9. Carman, G.M.; Han, G.S. Phosphatidic Acid Phosphatase, a Key Enzyme in the Regulation of Lipid Synthesis. *J. Biol. Chem.* **2009**, *284*, 2593–2597. [\[CrossRef\]](#)
10. Carman, G.M.; Han, G.-S. Roles of Phosphatidate Phosphatase Enzymes in Lipid Metabolism. *Trends Biochem. Sci.* **2006**, *31*, 694–699. [\[CrossRef\]](#)
11. Exton, J.H. Phospholipase D: Enzymology, Mechanisms of Regulation, and Function. *Physiol. Rev.* **1997**, *77*, 303–320. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Craven, P.A.; Davidson, C.M.; DeRubertis, F.R. Increase in Diacylglycerol Mass in Isolated Glomeruli by Glucose from de Novo Synthesis of Glycerolipids. *Diabetes* **1990**, *39*, 667–674. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Thorens, B.; Mueckler, M. Glucose Transporters in the 21st Century. *Am. J. Physiol. Endocrinol. Metab.* **2010**, *298*, 141–145. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Jiang, X.; Yang, F.; Brailoiu, E.; Jakubowski, H.; Dun, N.J.; Schafer, A.I.; Yang, X.; Durante, W.; Wang, H. Differential Regulation of Homocysteine Transport in Vascular Endothelial and Smooth Muscle Cells. *Diabetes* **1993**, *42*, 80–89. [\[CrossRef\]](#)
15. Nishizuka, Y. Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase, C. *Science* **1992**, *258*, 607–614. [\[CrossRef\]](#)
16. Newton, A.C. Regulation of Protein Kinase, C. *Curr. Opin. Cell Biol.* **1997**, *9*, 161–167. [\[CrossRef\]](#)
17. Ebinu, J.O.; Bottorff, D.A.; Chan, E.Y.W.; Stang, S.L.; Dunn, R.J.; Stone, J.C. RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs. *Science* **1998**, *280*, 1082–1086. [\[CrossRef\]](#)
18. Lucas, P.; Ukhanov, K.; Leinders-Zufall, T.; Zufall, F. A Diacylglycerol-Gated Cation Channel in Vomeronasal Neuron Dendrites Is Impaired in TRPC2 Mutant Mice: Mechanism of Pheromone Transduction. *Neuron* **2003**, *40*, 551–561. [\[CrossRef\]](#)
19. Limatola, C.; Schaap, D.; Moolenaar, W.H.; van Blitterswijk, W.J. Phosphatidic Acid Activation of Protein Kinase C-Zeta Overexpressed in COS Cells: Comparison with Other Protein Kinase C Isoforms and Other Acidic Lipids. *Biochem. J.* **1994**, *304*, 1001–1008. [\[CrossRef\]](#)
20. Jones, D.R.; Sanjuan, M.A.; Mérida, I. Type I α Phosphatidylinositol 4-Phosphate 5-Kinase Is a Putative Target for Increased Intracellular Phosphatidic Acid. *FEBS Lett.* **2000**, *476*, 160–165. [\[CrossRef\]](#)

21. Ghosh, S.; Strum, J.C.; Sciorra, V.A.; Daniel, L.; Bell, R.M. Raf-1 Kinase Possesses Distinct Binding Domains for Phosphatidylserine and Phosphatidic Acid: Phosphatidic Acid Regulates the Translocation of Raf-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Stimulated Madin-Darby Canine Kidney Cells. *J. Biol. Chem.* **1996**, *271*, 8472–8480. [[CrossRef](#)] [[PubMed](#)]
22. Fang, Y.; Vilella-Bach, M.; Bachmann, R.; Flanagan, A.; Chen, J. Phosphatidic Acid-Mediated Mitogenic Activation of MTOR Signaling. *Science* **2001**, *294*, 1942–1945. [[CrossRef](#)] [[PubMed](#)]
23. Newton, A.C. Protein Kinase C: Perfectly Balanced. *Crit. Rev. Biochem. Mol. Biol.* **2018**, *53*, 208–230. [[CrossRef](#)] [[PubMed](#)]
24. Parker, P.J.; Coussens, L.; Totty, N.; Rhee, L.; Young, S.; Chen, E.; Stabel, S.; Waterfield, M.D.; Ullrich, A. The Complete Primary Structure of Protein Kinase C—The Major Phorbol Ester Receptor. *Science* **1986**, *233*, 853–859. [[CrossRef](#)] [[PubMed](#)]
25. Knopf, J.L.; Lee, M.H.; Sultzman, L.A.; Kriz, R.W.; Loomis, C.R.; Hewick, R.M.; Bell, R.M. Cloning and Expression of Multiple Protein Kinase C cDNAs. *Cell* **1986**, *46*, 491–502. [[CrossRef](#)]
26. Ohno, S.; Akita, Y.; Konno, Y.; Imajoh, S.; Suzuki, K. A Novel Phorbol Ester Receptor/Protein Kinase, NPKC, Distantly Related to the Protein Kinase C Family. *Cell* **1988**, *53*, 731–741. [[CrossRef](#)]
27. Ono, Y.; Fujii, T.; Ogita, K.; Kikkawa, U.; Igarashi, K.; Nishizuka, Y. The Structure, Expression, and Properties of Additional Members of the Protein Kinase C Family. *J. Biol. Chem.* **1988**, *263*, 6927–6932. [[CrossRef](#)]
28. Nakanishi, H.; Exton, J.H. Purification and Characterization of the ζ Isoform of Protein Kinase C from Bovine Kidney. *J. Biol. Chem.* **1992**, *267*, 16347–16354. [[CrossRef](#)]
29. Craven, P.A.; DeRubertis, F. Protein Kinase C Is Activated in Glomeruli from Streptozotocin Diabetic Rats. Possible Mediation by Glucose. *J. Clin. Investig.* **1989**, *83*, 1667–1675. [[CrossRef](#)]
30. Inoguchi, T.; Battan, R.; Handler, E.; Sportsman, J.R.; Heath, W.; King, G.L. Preferential Elevation of Protein Kinase C Isoform Beta II and Diacylglycerol Levels in the Aorta and Heart of Diabetic Rats: Differential Reversibility to Glycemic Control by Islet Cell Transplantation. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 11059–11063. [[CrossRef](#)]
31. Ayo, S.H.; Radnik, R.; Garoni, J.A.; Troyer, D.A.; Kreisberg, J.I. High Glucose Increases Diacylglycerol Mass and Activates Protein Kinase C in Mesangial Cell Cultures. *Am. J. Physiol. Physiol.* **1991**, *261*, F571–F577. [[CrossRef](#)] [[PubMed](#)]
32. Koya, D.; King, G.L. Protein Kinase C Activation and the Development of Diabetic Complications. *Diabetes* **1998**, *47*, 859–866. [[CrossRef](#)] [[PubMed](#)]
33. Menne, J.; Park, J.K.; Boehne, M.; Elger, M.; Lindschau, C.; Kirsch, T.; Meier, M.; Gueler, F.; Fiebeler, A.; Bahlmann, F.H.; et al. Diminished Loss of Proteoglycans and Lack of Albuminuria in Protein Kinase C- α -Deficient Diabetic Mice. *Diabetes* **2004**, *53*, 2101–2109. [[CrossRef](#)] [[PubMed](#)]
34. Ohshiro, Y.; Ma, R.C.; Yasuda, Y.; Hiraoka-Yamamoto, J.; Clermont, A.C.; Isshiki, K.; Yagi, K.; Arikawa, E.; Kern, T.S.; King, G.L. Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase C β -Null Mice. *Diabetes* **2006**, *55*, 3112–3120. [[CrossRef](#)]
35. Tuttle, K.R.; Bakris, G.L.; Toto, R.D.; McGill, J.B.; Hu, K.; Anderson, P.W. The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. *Diabetes Care* **2005**, *28*, 2686–2690. [[CrossRef](#)]
36. Shiba, T.; Inoguchi, T.; Sportsman, J.R.; Heath, W.F.; Bursell, S.; King, G.L. Correlation of Diacylglycerol Level and Protein Kinase C Activity in Rat Retina to Retinal Circulation. *Am. J. Physiol.* **1993**, *265*, E783–E793. [[CrossRef](#)]
37. Derubertis, F.R.; Craven, P.A. Activation of Protein Kinase C in Glomerular Cells in Diabetes: Mechanisms and Potential Links to the Pathogenesis of Diabetic Glomerulopathy. *Diabetes* **1994**, *43*, 1–8. [[CrossRef](#)]
38. Babazono, T.; Kapor-Drezgic, J.; Dlugosz, J.A.; Whiteside, C. Altered Expression and Subcellular Localization of Diacylglycerol-Sensitive Protein Kinase C Isoforms in Diabetic Rat Glomerular Cells. *Diabetes* **1998**, *47*, 668–676. [[CrossRef](#)]
39. Chiarelli, F.; Gaspari, S.; Marcovecchio, M.L. Role of Growth Factors in Diabetic Kidney Disease. *Horm. Metab. Res.* **2009**, *41*, 585–593. [[CrossRef](#)]
40. Reeves, W.B.; Andreoli, T.E. Transforming Growth Factor β Contributes to Progressive Diabetic Nephropathy. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 7667–7669. [[CrossRef](#)]
41. Arora, M.K.; Singh, U.K. Molecular Mechanisms in the Pathogenesis of Diabetic Nephropathy: An Update. *Vascul. Pharmacol.* **2013**, *58*, 259–271. [[CrossRef](#)] [[PubMed](#)]
42. Koya, D.; Jirousek, M.R.; Lin, Y.W.; Ishii, H.; Kuboki, K.; King, G.L. Characterization of Protein Kinase C β Isoform Activation on the Gene Expression of Transforming Growth Factor- β , Extracellular Matrix Components, and Prostanoids in the Glomeruli of Diabetic Rats. *J. Clin. Investig.* **1997**, *100*, 115–126. [[CrossRef](#)] [[PubMed](#)]
43. Hayashida, T.; Schnaper, H.W. High Ambient Glucose Enhances Sensitivity to TGF- β 1 via Extracellular Signal-Regulated Kinase and Protein Kinase C δ Activities in Human Mesangial Cells. *J. Am. Soc. Nephrol.* **2004**, *15*, 2032–2041. [[CrossRef](#)]
44. Riser, B.L.; Denichilo, M.; Cortes, P.; Baker, C.; Grondin, J.M.; Yee, J.; Narins, R.G. Regulation of Connective Tissue Growth Factor Activity in Cultured Rat Mesangial Cells and Its Expression in Experimental Diabetic Glomerulosclerosis. *J. Am. Soc. Nephrol.* **2000**, *11*, 25–38. [[CrossRef](#)] [[PubMed](#)]
45. Khamaisi, M.; Schrijvers, B.F.; De Vriese, A.S.; Raz, I.; Flyvbjerg, A. The Emerging Role of VEGF in Diabetic Kidney Disease. *Nephrol. Dial. Transplant.* **2003**, *18*, 1427–1430. [[CrossRef](#)] [[PubMed](#)]
46. Hoshi, S.; Tomari, S.; Hoshi, S.; Nomoto, K.I.; Kuromitsu, J.; Nagata, M. High Glucose Induced VEGF Expression via PKC and ERK in Glomerular Podocytes. *Biochem. Biophys. Res. Commun.* **2002**, *290*, 177–184. [[CrossRef](#)] [[PubMed](#)]

47. Xia, L.; Wang, H.; Munk, S.; Frecker, H.; Goldberg, H.J.; Fantus, I.G.; Whiteside, C.I. Reactive Oxygen Species, PKC- α 1, and PKC- ζ Mediate High-Glucose-Induced Vascular Endothelial Growth Factor Expression in Mesangial Cells. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *293*, 1280–1288. [\[CrossRef\]](#)
48. Thallas-Bonke, V.; Thorpe, S.R.; Coughlan, M.T.; Fukami, K.; Yap, F.Y.T.; Sourris, K.C.; Penfold, S.A.; Bach, L.A.; Cooper, M.E.; Forbes, J.M. Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy through a Protein Kinase C- α -Dependent Pathway. *Diabetes* **2008**, *57*, 460–469. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Ishii, H.; Jirousek, M.R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S.E.; Kern, T.S.; Ballas, L.M.; Heath, W.F.; et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor. *Science* **1996**, *272*, 728–731. [\[CrossRef\]](#)
50. Koya, D.; Haneda, M.; Nakagawa, H.; Isshiki, K.; Sato, H.; Maeda, S.; Sugimoto, T.; Yasuda, H.; Kashiwagi, A.; Ways, D.K.; et al. Amelioration of Accelerated Diabetic Mesangial Expansion by Treatment with a PKC β Inhibitor in Diabetic Db/Db Mice, a Rodent Model for Type 2 Diabetes. *FASEB J.* **2000**, *14*, 439–447. [\[CrossRef\]](#)
51. Sheetz, M.J.; Aiello, L.P.; Davis, M.D.; Danis, R.; Bek, T.; Cunha-Vaz, J.; Shahri, N.; Berg, P.H. The Effect of the Oral PKC β Inhibitor Ruboxistaurin on Vision Loss in Two Phase 3 Studies. *Investig. Ophthalmol. Vis. Sci.* **2013**, *54*, 1750–1757. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Meier, M.; Park, J.K.; Overheu, D.; Kirsch, T.; Lindschau, C.; Gueler, F.; Leitges, M.; Menne, J.; Haller, H. Deletion of Protein Kinase C- β Isoform in Vivo Reduces Renal Hypertrophy but Not Albuminuria in the Streptozotocin-Induced Diabetic Mouse Model. *Diabetes* **2007**, *56*, 346–354. [\[CrossRef\]](#)
53. Kanoh, H.; Yamada, K.; Sakane, F. Diacylglycerol Kinase: A Key Modulator of Signal Transduction? *Trends Biochem. Sci.* **1990**, *15*, 47–50. [\[CrossRef\]](#)
54. Sakane, F.; Imai, S.I.; Kai, M.; Yasuda, S.; Kanoh, H. Diacylglycerol Kinases: Why so Many of Them? *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2007**, *1771*, 793–806. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Topham, M.K.; Prescott, S.M. Mammalian diacylglycerol kinases, a Family of Lipid Kinases with Signaling Functions. *J. Biol. Chem.* **1999**, *274*, 11447–11450. [\[CrossRef\]](#)
56. Van Blitterswijk, W.J.; Houssa, B. Properties and Functions of Diacylglycerol Kinases. *Cell. Signal.* **2000**, *12*, 595–605. [\[CrossRef\]](#)
57. Kanoh, H.; Yamada, K.; Sakane, F. Diacylglycerol Kinases: Emerging Downstream Regulators in Cell Signaling Systems. *J. Biochem.* **2002**, *131*, 629–633. [\[CrossRef\]](#)
58. Sakane, F.; Yamada, K.; Kanoh, H.; Yokoyama, C.; Tanabe, T. Porcine Diacylglycerol Kinase Sequence Has Zinc Finger and E-F Hand Motifs. *Nature* **1990**, *344*, 345–348. [\[CrossRef\]](#)
59. Klauck, T.M.; Xu, X.; Mousseau, B.; Jaken, S. Cloning and Characterization of a Glucocorticoid-Induced Diacylglycerol Kinase. *J. Biol. Chem.* **1996**, *271*, 19781–19788. [\[CrossRef\]](#)
60. Letwin, K.; Yee, S.P.; Pawson, T. Novel Protein-Tyrosine Kinase CDNAs Related to Fps/Fes and Eph Cloned Using Anti-Phosphotyrosine Antibody. *Oncogene* **1988**, *3*, 621–627.
61. Imai, S.; Kai, M.; Yasuda, S.; Kanoh, H.; Sakane, F. Identification and Characterization of a Novel Human Type II Diacylglycerol Kinase, DGK Kappa. *J. Biol. Chem.* **2005**, *280*, 39870–39881. [\[CrossRef\]](#)
62. Tang, W.; Bunting, M.; Zimmerman, G.A.; McIntyre, T.M.; Prescott, S.M. Molecular Cloning of a Novel Human Diacylglycerol Kinase Highly Selective for Arachidonate-Containing Substrates. *J. Biol. Chem.* **1996**, *271*, 10237–10241. [\[CrossRef\]](#)
63. Bunting, M.; Tang, W.; Zimmerman, G.A.; McIntyre, T.M.; Prescott, S.M. Molecular Cloning and Characterization of a Novel Human Diacylglycerol Kinase Zeta. *J. Biol. Chem.* **1996**, *271*, 10230–10236. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Goto, K.; Kondo, H. A 104-KDa Diacylglycerol Kinase Containing Ankyrin-like Repeats Localizes in the Cell Nucleus. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 11196–11201. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Ding, L.; Traer, E.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. The Cloning and Characterization of a Novel Human Diacylglycerol Kinase, DGKiota. *J. Biol. Chem.* **1998**, *273*, 32746–32752. [\[PubMed\]](#)
66. Houssa, B.; Schaap, D.; Van Der Wal, J.; Goto, K.; Kondo, H.; Yamakawa, A.; Shibata, M.; Takenawa, T.; Van Blitterswijk, W.J. Cloning of a Novel Human Diacylglycerol Kinase (DGK θ) Containing Three Cysteine-Rich Domains, a Proline-Rich Region, and a Pleckstrin Homology Domain with an Overlapping Ras-Associating Domain. *J. Biol. Chem.* **1997**, *272*, 10422–10428. [\[CrossRef\]](#) [\[PubMed\]](#)
67. Rigotti, A. Absorption, Transport, and Tissue Delivery of Vitamin E. *Mol. Asp. Med.* **2007**, *28*, 423–436. [\[CrossRef\]](#)
68. Traber, M.G.; Atkinson, J. Vitamin E, Antioxidant and Nothing More. *Free Radic. Biol. Med.* **2007**, *43*, 4–15. [\[CrossRef\]](#) [\[PubMed\]](#)
69. Koya, D.; Lee, I.K.; Ishii, H.; Kanoh, H.; King, G.L. Prevention of Glomerular Dysfunction in Diabetic Rats by Treatment with D-Alpha-Tocopherol. *J. Am. Soc. Nephrol.* **1997**, *8*, 426–435.
70. Tada, H.; Ishii, H.; Isogai, S. Protective Effect of D- α -Tocopherol on the Function of Human Mesangial Cells Exposed to High Glucose Concentrations. *Metabolism* **1997**, *46*, 779–784. [\[CrossRef\]](#)
71. Kakehi, T.; Yagi, K.; Saito, N.; Shirai, Y. Effects of Vitamin E and Its Derivatives on Diabetic Nephropathy in Rats and Identification of Diacylglycerol Kinase Subtype Involved in the Improvement of Diabetic Nephropathy. *Funct. Foods Health Dis.* **2017**, *7*, 816–832. [\[CrossRef\]](#)
72. Shirai, Y.; Segawa, S.; Kuriyama, M.; Goto, K.; Sakai, N.; Naoaki, S. Subtype-Specific Translocation of Diacylglycerol Kinase α and γ and Its Correlation with Protein Kinase C. *J. Biol. Chem.* **2000**, *275*, 24760–24766. [\[CrossRef\]](#) [\[PubMed\]](#)
73. Fukunaga-Takenaka, R.; Shirai, Y.; Yagi, K.; Adachi, N.; Sakai, N.; Merino, E.; Merida, I.; Saito, N. Importance of Chroman Ring and Tyrosine Phosphorylation in the Subtype-Specific Translocation and Activation of Diacylglycerol Kinase α by D- α -Tocopherol. *Genes Cells* **2005**, *10*, 311–319. [\[CrossRef\]](#) [\[PubMed\]](#)

74. Tasinato, A.; Boscoboinik, D.; Bartoli, G.M.; Maroni, P.; Azzi, A. D- α -Tocopherol Inhibition of Vascular Smooth Muscle Cell Proliferation Occurs at Physiological Concentrations, Correlates with Protein Kinase C Inhibition, and Is Independent of Its Antioxidant Properties. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 12190–12194. [\[CrossRef\]](#)
75. Pryor, W.A.; Cornicelli, J.A.; Devall, L.J.; Tait, B.; Trivedi, B.K.; Witiak, D.T.; Wu, M. A Rapid Screening Test To Determine the Antioxidant Potencies of Natural and Synthetic Antioxidants. *J. Org. Chem.* **1993**, *58*, 3521–3532. [\[CrossRef\]](#)
76. Atsumi, H.; Kitada, M.; Kanasaki, K.; Koya, D. Reversal of Redox-Dependent Inhibition of Diacylglycerol Kinase by Antioxidants in Mesangial Cells Exposed to High Glucose. *Mol. Med. Rep.* **2011**, *4*, 923–927. [\[CrossRef\]](#)
77. Hayashi, D.; Yagi, K.; Song, C.; Ueda, S.; Yamanoue, M.; Topham, M.; Suzaki, T.; Saito, N.; Emoto, N.; Shirai, Y. Diacylglycerol Kinase Alpha Is Involved in the Vitamin E-Induced Amelioration of Diabetic Nephropathy in Mice. *Sci. Rep.* **2017**, *7*, 2597. [\[CrossRef\]](#) [\[PubMed\]](#)
78. Vasavada, N.; Agarwal, R. Role of Oxidative Stress in Diabetic Nephropathy. *Adv. Chronic Kidney Dis.* **2005**, *12*, 146–154. [\[CrossRef\]](#)
79. Kaneko, Y.K.; Kobayashi, Y.; Motoki, K.; Nakata, K.; Miyagawa, S.; Yamamoto, M.; Hayashi, D.; Shirai, Y.; Sakane, F.; Ishikawa, T. Depression of Type I Diacylglycerol Kinases in Pancreatic β -Cells from Male Mice Results in Impaired Insulin Secretion. *Endocrinology* **2013**, *154*, 4089–4098. [\[CrossRef\]](#) [\[PubMed\]](#)
80. Chibalin, A.V.; Leng, Y.; Vieira, E.; Krook, A.; Björnholm, M.; Long, Y.C.; Kotova, O.; Zhong, Z.; Sakane, F.; Steiler, T.; et al. Downregulation of Diacylglycerol Kinase Delta Contributes to Hyperglycemia-Induced Insulin Resistance. *Cell* **2008**, *132*, 375–386. [\[CrossRef\]](#)
81. Lonn, E.; Yusuf, S.; Hoogwerf, B.; Pogue, J.; Yi, Q.; Zinman, B.; Bosch, J.; Dagenais, G.; Mann, J.F.E.; Gerstein, H.C. Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes Results of the HOPE Study and micro-hope substudy on behalf of the heart outcomes prevention evaluation (hope) investigators. *Diabetes Care* **2002**, *25*, 1919–1927. [\[CrossRef\]](#) [\[PubMed\]](#)
82. Di Vincenzo, A.; Tana, C.; El Hadi, H.; Pagano, C.; Vettor, R.; Rossato, M. Antioxidant, Anti-Inflammatory, and Metabolic Properties of Tocopherols and Tocotrienols: Clinical Implications for Vitamin E Supplementation in Diabetic Kidney Disease. *Int. J. Mol. Sci.* **2019**, *20*, 5101. [\[CrossRef\]](#) [\[PubMed\]](#)
83. Tan, S.M.Q.; Chiew, Y.; Ahmad, B.; Kadir, K.A. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial. *Nutrients* **2018**, *10*, 1315. [\[CrossRef\]](#)
84. Yokozawa, T.; Nakagawa, T.; Oya, T.; Okubo, T.; Juneja, L.R. Green Tea Polyphenols and Dietary Fibre Protect against Kidney Damage in Rats with Diabetic Nephropathy. *J. Pharm. Pharmacol.* **2010**, *57*, 773–780. [\[CrossRef\]](#)
85. Yamabe, N.; Yokozawa, T.; Oya, T.; Kim, M. Therapeutic Potential of (-)-Epigallocatechin 3-O-Gallate on Renal Damage in Diabetic Nephropathy Model Rats. *J. Pharmacol. Exp. Ther.* **2006**, *319*, 228–236. [\[CrossRef\]](#) [\[PubMed\]](#)
86. Mohabbulla Mohib, M.; Fazla Rabby, S.M.; Paran, T.Z.; Mehedee Hasan, M.; Ahmed, I.; Hasan, N.; Abu Taher Sagor, M.; Mohiuddin, S. Protective Role of Green Tea on Diabetic Nephropathy—A Review. *Cogent. Biol.* **2016**, *2*, 1248166. [\[CrossRef\]](#)
87. Hayashi, D.; Ueda, S.; Yamanoue, M.; Saito, N.; Ashida, H.; Shirai, Y. Epigallocatechin-3-Gallate Activates Diacylglycerol Kinase Alpha via a 67 KDa Laminin Receptor: A Possibility of Galloylated Catechins as Functional Food to Prevent and/or Improve Diabetic Renal Dysfunctions. *J. Funct. Foods* **2015**, *15*, 561–569. [\[CrossRef\]](#)
88. Hayashi, D.; Wang, L.; Ueda, S.; Yamanoue, M.; Ashida, H. The Mechanisms of Ameliorating Effect of a Green Tea Polyphenol on Diabetic Nephropathy Based on Diacylglycerol Kinase α . *Sci. Rep.* **2020**, *10*, 11790. [\[CrossRef\]](#)
89. Borges, C.M.; Papadimitriou, A.; Duarte, D.A.; Lopes De Faria, J.M.; Lopes De Faria, J.B. The Use of Green Tea Polyphenols for Treating Residual Albuminuria in Diabetic Nephropathy: A Double-Blind Randomised Clinical Trial. *Sci. Rep.* **2016**, *6*, 28282. [\[CrossRef\]](#)
90. Ueda, M.; Nishiumi, S.; Nagayasu, H.; Fukuda, I.; Yoshida, K.I.; Ashida, H. Epigallocatechin Gallate Promotes GLUT4 Translocation in Skeletal Muscle. *Biochem. Biophys. Res. Commun.* **2008**, *377*, 286–290. [\[CrossRef\]](#)
91. Shahwan, M.; Alhumaydhi, F.; Ashraf, G.M.; Hasan, P.M.Z.; Shamsi, A. Role of Polyphenols in Combating Type 2 Diabetes and Insulin Resistance. *Int. J. Biol. Macromol.* **2022**, *206*, 567–579. [\[CrossRef\]](#)
92. Isbrucker, R.A.; Edwards, J.A.; Wolz, E.; Davidovich, A.; Bausch, J. Safety Studies on Epigallocatechin Gallate (EGCG) Preparations. Part 2: Dermal, Acute and Short-Term Toxicity Studies. *Food Chem. Toxicol.* **2006**, *44*, 636–650. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Ullmann, U.; Haller, J.; Decourt, J.D.; Girault, J.; Spitzer, V.; Weber, P. Plasma-Kinetic Characteristics of Purified and Isolated Green Tea Catechin Epigallocatechin Gallate (EGCG) after 10 Days Repeated Dosing in Healthy Volunteers. *Int. J. Vitam. Nutr. Res.* **2004**, *74*, 269–278. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Hayashi, D.; Ueda, S.; Yamanoue, M.; Ashida, H.; Shirai, Y. Amelioration of Diabetic Nephropathy by Oral Administration of D- α -Tocopherol and Its Mechanisms. *Biosci. Biotechnol. Biochem.* **2018**, *82*, 65–73. [\[CrossRef\]](#) [\[PubMed\]](#)
95. Mohan, T.; Velusamy, P.; Chakrapani, L.N.; Srinivasan, A.K.; Singh, A.; Johnson, T.; Periandavan, K. Impact of EGCG Supplementation on the Progression of Diabetic Nephropathy in Rats: An Insight into Fibrosis and Apoptosis. *J. Agric. Food Chem.* **2017**, *65*, 8028–8036. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Mundel, P.; Kriz, W. Structure and Function of Podocytes: An Update. *Anat. Embryol.* **1995**, *192*, 385–397. [\[CrossRef\]](#) [\[PubMed\]](#)
97. Mundel, P. Podocyte Biology and Response to Injury. *J. Am. Soc. Nephrol.* **2004**, *13*, 3005–3015. [\[CrossRef\]](#)
98. Li, J.J.; Kwak, S.J.; Jung, D.S.; Kim, J.J.; Yoo, T.H.; Ryu, D.R.; Han, S.H.; Choi, H.Y.; Lee, J.E.; Moon, S.J.; et al. Podocyte Biology in Diabetic Nephropathy. *Kidney Int.* **2007**, *72*, S36–S42. [\[CrossRef\]](#)

99. Quack, I.; Woznowski, M.; Potthoff, S.A.; Palmer, R.; Königshausen, E.; Sivritas, S.; Schiffer, M.; Stegbauer, J.; Vonend, O.; Rump, L.C.; et al. PKC α Mediates β -Arrestin2-Dependent Nephrin Endocytosis in Hyperglycemia. *J. Biol. Chem.* **2011**, *286*, 13959–13970. [CrossRef]
100. Kerjaschki, D.; Ojha, P.P.; Susani, M.; Horvat, R.; Binder, S.; Hovorka, A.; Hillemanns, P.; Pytela, R. A Beta 1-Integrin Receptor for Fibronectin in Human Kidney Glomeruli. *Am. J. Pathol.* **1989**, *134*, 481–489.
101. Adler, S. Characterization of Glomerular Epithelial Cell Matrix Receptors. *Am. J. Pathol.* **1992**, *141*, 571. [PubMed]
102. Rainero, E.; Caswell, P.T.; Muller, P.A.J.; Grindlay, J.; McCaffrey, M.W.; Zhang, Q.; Wakelam, M.J.O.; Vousden, K.H.; Graziani, A.; Norman, J.C. Diacylglycerol Kinase α Controls RCP-Dependent Integrin Trafficking to Promote Invasive Migration. *J. Cell Biol.* **2012**, *196*, 277–295. [CrossRef]
103. Rainero, E.; Cianflone, C.; Porporato, P.E.; Chianale, F.; Malacarne, V.; Bettio, V.; Ruffo, E.; Ferrara, M.; Benecchia, F.; Capello, D.; et al. The Diacylglycerol Kinase α /Atypical PKC/B1 Integrin Pathway in SDF-1 α Mammary Carcinoma Invasiveness. *PLoS ONE* **2014**, *9*, 97144. [CrossRef] [PubMed]
104. Dominguez, C.L.; Floyd, D.H.; Xiao, A.; Mullins, G.R.; Benjamin, A.; Xin, W.; Yacur, M.N.; Abounader, R.; Lee, J.K.; Mustata, G.; et al. Therapeutic Target in Glioblastoma and Other Cancers. *Cancer Discov.* **2013**, *3*, 782–797. [CrossRef] [PubMed]
105. Yanagisawa, K.; Yasuda, S.; Kai, M.; Imai, S.I.; Yamada, K.; Yamashita, T.; Jimbow, K.; Kanoh, H.; Sakane, F. Diacylglycerol Kinase α Suppresses Tumor Necrosis Factor- α -Induced Apoptosis of Human Melanoma Cells through NF-KB Activation. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2007**, *1771*, 462–474. [CrossRef]
106. Sakane, F.; Hoshino, F.; Ebina, M.; Sakai, H.; Takahashi, D. The Roles of Diacylglycerol Kinase α in Cancer Cell Proliferation and Apoptosis. *Cancers* **2021**, *13*, 5190. [CrossRef] [PubMed]
107. Yamamoto, T.; Sakai, H.; Sakane, F. EF-Hand Motifs of Diacylglycerol Kinase α Interact Intra-Molecularly with Its C1 Domains. *FEBS Open Biol.* **2014**, *4*, 387–392. [CrossRef] [PubMed]
108. Sakane, F.; Yamada, K.; Imai, S.I.; Kanoh, H. Porcine 80-KDa Diacylglycerol Kinase Is a Calcium-Binding and Calcium/Phospholipid-Dependent Enzyme and Undergoes Calcium-Dependent Translocation. *J. Biol. Chem.* **1991**, *266*, 7096–7100. [CrossRef]
109. Abe, T.; Lu, X.; Jiang, Y.; Boccone, C.E.; Qian, S.; Vattem, K.M.; Wek, R.C.; Walsh, J.P. Site-Directed Mutagenesis of the Active Site of Diacylglycerol Kinase α : Calcium and Phosphatidylserine Stimulate Enzyme Activity via Distinct Mechanisms. *Biochem. J.* **2003**, *375*, 673–680. [CrossRef]
110. Ciprés, A.; Carrasco, S.; Merino, E.; Díaz, E.; Krishna, U.M.; Falck, J.R.; Martínez-A, C.; Mérida, I. Regulation of Diacylglycerol Kinase α by Phosphoinositide 3-Kinase Lipid Products. *J. Biol. Chem.* **2003**, *278*, 35629–35635. [CrossRef]
111. Keiko, Y.; Fumio, S. The Different Effects of Sphingosine on Diacylglycerol Kinase Isozymes in Jurkat Cells, a Human T-Cell Line. *Biochim. Biophys. Acta Lipids Lipid Metab.* **1993**, *1169*, 211–216. [CrossRef]
112. Keiko, Y.; Fumio, S.; Shin-ichi, I.; Haruo, T. Sphingosine Activates Cellular Diacylglycerol Kinase in Intact Jurkat Cells, a Human T-Cell Line. *Biochim. Biophys. Acta Lipids Lipid Metab.* **1993**, *1169*, 217–224. [CrossRef]
113. Liu, K.; Kunii, N.; Sakuma, M.; Yamaki, A.; Mizuno, S.; Sato, M.; Sakai, H.; Kado, S.; Kumagai, K.; Kojima, H.; et al. A Novel Diacylglycerol Kinase α -Selective Inhibitor, CU-3, Induces Cancer Cell Apoptosis and Enhances Immune Response. *J. Lipid Res.* **2016**, *57*, 368–379. [CrossRef]
114. Hayashi, D.; Tsumagari, R.; Liu, K.; Ueda, S.; Yamanoue, M.; Sakane, F.; Shirai, Y. Screening of Subtype-Specific Activators and Inhibitors for Diacylglycerol Kinase. *J. Biochem.* **2019**, *165*, 517–522. [CrossRef]
115. Takahashi, D.; Suzuki, K.; Sakamoto, T.; Iwamoto, T.; Murata, T.; Sakane, F. Crystal Structure and Calcium-Induced Conformational Changes of Diacylglycerol Kinase α EF-Hand Domains. *Protein Sci.* **2019**, *28*, 694–706. [CrossRef] [PubMed]
116. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A.; et al. Highly Accurate Protein Structure Prediction with AlphaFold. *Nature* **2021**, *596*, 583–589. [CrossRef] [PubMed]
117. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. *Nucleic Acids Res.* **2022**, *50*, D439–D444. [CrossRef]
118. Aulakh, S.S.; Bozelli, J.C.; Epand, R.M. Exploring the AlphaFold Predicted Conformational Properties of Human Diacylglycerol Kinases. *J. Phys. Chem. B* **2022**, *126*, 7172–7183. [CrossRef] [PubMed]
119. Merino, E.; Sanjuán, M.A.; Moraga, I.; Ciprés, A.; Mérida, I. Role of the Diacylglycerol Kinase α -Conserved Domains in Membrane Targeting in Intact T Cells. *J. Biol. Chem.* **2007**, *282*, 35396–35404. [CrossRef]
120. Matsubara, T.; Ikeda, M.; Kiso, Y.; Sakuma, M.; Yoshino, K.I.; Sakane, F.; Merida, I.; Saito, N.; Shirai, Y. C-Abl Tyrosine Kinase Regulates Serum-Induced Nuclear Export of Diacylglycerol Kinase α by Phosphorylation at Tyr-218. *J. Biol. Chem.* **2012**, *287*, 5507–5517. [CrossRef]
121. Azzi, A.; Stocker, A. Vitamin E: Non-Antioxidant Roles. *Prog. Lipid Res.* **2000**, *39*, 231–255. [CrossRef]
122. Rao, N.C.; Barsky, S.H.; Terranova, V.P.; Liotta, L.A. Isolation of a Tumor Cell Laminin Receptor. *Biochem. Biophys. Res. Commun.* **1983**, *111*, 804–808. [CrossRef]
123. Malinoff, H.L.; Wicha, M.S. Isolation of a Cell Surface Receptor Protein for Laminin from Murine Fibrosarcoma Cells. *J. Cell Biol.* **1983**, *96*, 1475–1479. [CrossRef]
124. Lesot, H.; Kühn, U.; von der Mark, K.; Mark, K. Isolation of a Laminin-Binding Protein from Muscle Cell Membranes. *EMBO J.* **2018**, *2*, 861–865. [CrossRef]

125. Gauczynski, S.; Peyrin, J.; Haõ, Â.; Leucht, C.; Hundt, C.; Rieger, R.; Krasemann, S.; Deslys, J.; Dormont, D.; Weiss, S.; et al. The 37-KDa/67-KDa Laminin Receptor Acts as the Cell-Surface Receptor for the Cellular Prion Protein. *EMBO J.* **2001**, *20*, 5863–5875. [[CrossRef](#)]
126. Wang, K.S.; Kuhn, R.J.; Strauss, E.G.; Ou, S.; Strauss, J.H. High-Affinity Laminin Receptor Is a Receptor for Sindbis Virus in Mammalian Cells. *J. Virol.* **1992**, *66*, 4992–5001. [[CrossRef](#)]
127. Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A Receptor for Green Tea Polyphenol EGCG. *Nat. Struct. Mol. Biol.* **2004**, *11*, 380–381. [[CrossRef](#)]
128. Umeda, D.; Yano, S.; Yamada, K.; Tachibana, H. Green Tea Polyphenol Epigallocatechin-3-Gallate Signaling Pathway through 67-KDa Laminin Receptor. *J. Biol. Chem.* **2008**, *283*, 3050–3058. [[CrossRef](#)]
129. Kumazoe, M.; Sugihara, K.; Tsukamoto, S.; Huang, Y.; Tsurudome, Y.; Suzuki, T.; Suemasu, Y.; Ueda, N.; Yamashita, S.; Kim, Y.; et al. 67-KDa Laminin Receptor Increases CGMP to Induce Cancer-Selective Apoptosis. *J. Clin. Investig.* **2013**, *123*, 787–799. [[CrossRef](#)] [[PubMed](#)]
130. Hong Byun, E.; Fujimura, Y.; Yamada, K.; Tachibana, H. TLR4 Signaling Inhibitory Pathway Induced by Green Tea Polyphenol Epigallocatechin-3-Gallate through 67-KDa Laminin Receptor. *J. Immunol.* **2010**, *185*, 33–45. [[CrossRef](#)] [[PubMed](#)]
131. Tsukamoto, S.; Huang, Y.; Umeda, D.; Yamada, S.; Yamashita, S.; Kumazoe, M.; Kim, Y.; Murata, M.; Yamada, K.; Tachibana, H. 67-KDa Laminin Receptor-Dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-Specific Antitumor Activity Overcoming Drug Resistance. *J. Biol. Chem.* **2014**, *289*, 32671–32681. [[CrossRef](#)] [[PubMed](#)]
132. Kumazoe, M.; Kadamatsu, M.; Bae, J.; Otsuka, Y.; Fujimura, Y. Src Mediates Epigallocatechin-3-O-Gallate-Elicited Acid Sphingomyelinase Activation. *Molecules* **2020**, *25*, 5481. [[CrossRef](#)] [[PubMed](#)]
133. Hayashi, D.; Mouchlis, V.D.; Okamoto, S.; Namba, T.; Wang, L.; Li, S.; Ueda, S.; Yamanoue, M.; Tachibana, H.; Arai, H.; et al. Vitamin E Functions by Association with a Novel Binding Site on the 67 KDa Laminin Receptor Activating Diacylglycerol Kinase. *J. Nutr. Biochem.* **2022**, *110*, 109129. [[CrossRef](#)] [[PubMed](#)]
134. Bhat, K.P.L.; Aldape, K. Not Expecting the Unexpected: Diacylglycerol Kinase Alpha as a Cancer Target. *Cancer Discov.* **2013**, *3*, 726–727. [[CrossRef](#)]
135. Krishna, S.; Zhong, X.P. Regulation of Lipid Signaling by Diacylglycerol Kinases during T Cell Development and Function. *Front. Immunol.* **2013**, *4*, 178. [[CrossRef](#)]
136. Velnati, S.; Ruffo, E.; Massarotti, A.; Talmon, M.; Varma, K.S.S.; Gesu, A.; Fresu, L.G.; Snow, A.L.; Bertoni, A.; Capello, D.; et al. Identification of a Novel DGK α Inhibitor for XLP-1 Therapy by Virtual Screening. *Eur. J. Med. Chem.* **2019**, *164*, 378–390. [[CrossRef](#)]